跳至主要内容
临床试验/ACTRN12619000445178
ACTRN12619000445178已完成未知

ong-term clinical outcomes in Synovitis Acne Pustulosis Hyperostosis and Osteitis syndrome

Graeme Carroll0 个研究点目标入组 21 人开始时间: 2019年3月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
21

研究概览

简要总结

This report illustrates the broad spectrum of disease presentations and severity in SAPHO. It also illustrates the disease progression over time and the responses to a variety of treatments or, in three cases, with no treatment. Mostly good or very good long-term treatment outcomes were observed in disease modifying agents (DMARDs) and biologic treatments. Suboptimal treatment may be associated with poorer clinical outcomes and greater skeletal damage. Just over half the participants studied were treated with biologic agents. Nine of 12 (75%) had a good primary response, extending for up to 14 years. It was concluded that TNFi therapy is mostly effective and moderately sustainable. The study has several limitations. The numbers of participants are small; most patients studies were Caucasian and therefore the results may not be generalizable to the wider population.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of SAPHO as defined as multifocal osteitis with/without skin symptoms, sterile acute or chronic joint inflammation with either palmoplantar pustulosis or psoriasis, or acne or hidradenitis, with sterile osteitis with any one of these sets of criteria deemed sufficient for diagnosis.

排除标准

  • Those people that did not meet the criteria required to be diagnosed with SAPHO (multifocal osteitis with/without skin symptoms, sterile acute or chronic joint inflammation with either palmoplantar pustulosis or psoriasis, or acne or hidradenitis, with sterile osteitis with any one of these sets of criteria).

研究者

发起方
Graeme Carroll

相似试验